• Next-generation sequencing based detection in a patient with three synchronous primary tumors.
    • Wu T, Wan J, Xia K, Yang MQ, Feng L, Yin L, Chen C.
    • Front Oncol. 2022 Jun 24;12:910264. doi: 10.3389/fonc.2022.910264.
  • LitAlert ~~ GeneLit.com

    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 June 25. doi: 10.1038/s41416-022-01900-9. Epub ahead of print.
    • Genetic testing and its clinical application in prostate cancer management: Consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam M, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jun 24;12:962958. doi: 10.3389/fonc.2022.962958.
    • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
    • Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW.
    • Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2.

    Identifier: NCT02719977: A Phase I Study of CX5461. (ClinicalTrials.gov)

    • Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    • Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K.
    • Eur Urol. 2022 Jun 21:S0302-2838(22)02407-1. doi: 10.1016/j.eururo.2022.05.030. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • New Adjuvant Treatment for High-Risk Early Breast Cancer.
    • Aschenbrenner DS.
    • Am J Nurs. 2022 Jul 1;122(7):26. doi: 10.1097/01.NAJ.0000842240.11650.1d.
    • News
    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.
    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Parra Cuentas ER, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Jun 23:clincanres.1278.2021. doi: 10.1158/1078-0432.CCR-21-1278. Epub ahead of print.
    • Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell C, Salih Z, Woodward ER, Lalloo F, Shaw J, Desai S, Crosbie EJ, Edmondson RJ, Schlecht H, Wallace AJ, Jayson GC, Evans DGR.
    • J Clin Pathol. 2022 Jun 23:jclinpath-2022-208369. doi: 10.1136/jcp-2022-208369. Epub ahead of print.
    • Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.
    • Colosini A, Bernardi S, Foroni C, Pasinetti N, Guerini AE, Russo D, Bresciani R, Tomasi C, Magrini SM, Bardoscia L, Triggiani L.
    • Biomedicines. 2022 Jun 4;10(6):1321. doi: 10.3390/biomedicines10061321.
    • Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.
    • Darabi S, Braxton D, Homer J, Brodie T, Holnagel D, Eisenberg B, Demeure MJ.
    • JCO Precis Oncol. 2022 Jun;6:e2200090. doi: 10.1200/PO.22.00090.
    • Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
    • Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzoni M, Frassineti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A.
    • Eur J Cancer. 2022 Jun 21;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    • Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    • BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
    • What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    • Loehr A, Petrylak D, Watkins SP.
    • Front Oncol. 2022 Jun 20;12:951348. doi: 10.3389/fonc.2022.951348.
    • Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.
    • Kurian AW, Abrahamse P, Hamilton AS, Caswell-Jin JL, Gomez SL, Hofer TJ, Ward KC, Katz SJ.
    • JNCI Cancer Spectr. 2022 Jun 20:pkac045. doi: 10.1093/jncics/pkac045. Epub ahead of print.
    • A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer.
    • Rutherford CL, Goodman D, Lannigan A.
    • Eur J Surg Oncol. 2022 Jun 10:S0748-7983(22)00488-7. doi: 10.1016/j.ejso.2022.06.004. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Jun 18. doi: 10.1245/s10434-022-12048-4. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Jun 18:S0960-9776(22)00104-7. doi: 10.1016/j.breast.2022.06.003. Epub ahead of print.
    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    • Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J.
    • Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y.
    • Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    • Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH.
    • Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350. Epub ahead of print.
    • Optimizing Treatment Selection and Sequencing Decisions for First-Line Maintenance Therapy of Newly Diagnosed Advanced Ovarian Cancer– International considerations amongst upper middle- and high-income countries (UMIC and HIC).
    • Goh JCH, Mclaren Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A.
    • Gynecol Oncol Rep. 2022 Jun 17;101028. doi: 10.1016/j.gore.2022.101028.
    • The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
    • Kensler KH, Baichoo S, Pathania S, Rebbeck TR.
    • NPJ Precis Oncol. 2022 Jun 17;6(1):39. doi: 10.1038/s41698-022-00284-6.
    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review
  • LitAlert ~~ GeneLit.com

    • Surveillance mammography after treatment for male breast cancer.
    • Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ.
    • Breast Cancer Res Treat. 2022 Jun 17. doi: 10.1007/s10549-022-06645-w. Epub ahead of print.
    • A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
    • Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
    • Curr Oncol. 2022 Jun 17;29(6):4354-4369. doi: 10.3390/curroncol29060348.
    • Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    • Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.
    • Fam Cancer. 2022 Jun 17. doi: 10.1007/s10689-022-00300-5. Epub ahead of print.
    • The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis.
    • Atwal A, Snowsill T, Cabrera Dandy M, Krum T, Newton C, Evans DG, Crosbie EJ, Ryan NAJ.
    • Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165. Epub ahead of print.
    • Meta-Analysis
  • LitAlert ~~ GeneLit.com

    • PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
    • Congregado B, Rivero I, Osmán I, Sáez C, Medina López R.
    • Biomedicines. 2022 Jun 15;10(6):1416. doi: 10.3390/biomedicines10061416.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    • Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
    • Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.